Assertio Holdings | DEPO - Selling And Administration Expenses


Assertio Holdings reported $16.73M in Selling and Administration Expenses for its fiscal quarter ending in September of 2024.





Selling And Administration Expenses Change Date
ANI Pharmaceuticals USD 73.66M 9.14M Mar/2026
Assertio Holdings USD 16.73M 1.66M Sep/2024
Aurora Cannabis CAD 40.62M 1.17M Dec/2025
Cara Therapeutics USD 2.19M 2.45M Sep/2025
Daiichi Sankyo JPY 228.23B 39.15B Dec/2025
Ironwood Pharmaceuticals USD 33.33M 2.78M Dec/2024
J&J USD 6.03B 719M Mar/2026
Knight Therapeutics CAD 35.45M 4.43M Dec/2025
Merck USD 2.67B 180M Mar/2026
Nektar Therapeutics USD 10.17M 10.17M Dec/2025
Omeros USD 11.32M 2.48M Sep/2024
Pfizer USD 2.92B 1.16B Mar/2026
Teva Pharmaceutical Industries USD 1000M 120M Mar/2026